NASDAQ: HINDVyome Holdings Inc Stock
$2.59-0.02 (-0.77%)
Updated Feb 13, 2026
HIND Price
$2.59
Fair Value Price
N/A
Market Cap
$14.62M
52 Week Low
$1.75
52 Week High
$305.00
P/E
-0.02x
P/B
5.78x
P/S
3.41x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.19M
Earnings
-$11.35M
Gross Margin
62.4%
Operating Margin
-268.99%
Profit Margin
-270.6%
Debt to Equity
1.24
Operating Cash Flow
-$3M
Beta
0.56
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HIND Overview
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HIND's potential to beat the market
- HIND doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
HIND
RankedUnranked of 102
RankedUnranked of 102
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.27 | A | |
| $26.45 | A | |
| $24.26 | A |
Be the first to know about important HIND news, forecast changes, insider trades & much more!
HIND News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HIND scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HIND is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HIND is poor value based on its book value relative to its share price (5.78x), compared to the US Medical Devices industry average (3.64x)
P/B vs Industry Valuation
HIND is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more HIND due diligence checks available for Premium users.
Valuation
HIND price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.02x
Industry
22.17x
Market
43.92x
HIND price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.78x
Industry
3.64x
HIND is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HIND's financial health
Profit margin
Revenue
$34.6k
Net Income
-$8.4M
Profit Margin
-24,356.2%
HIND's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
HIND's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$7.0M
Liabilities
$3.1M
Debt to equity
1.24
HIND's short-term assets ($6.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HIND's short-term assets ($6.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HIND's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
HIND's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$4.3M
Investing
$0.0
Financing
-$2.2M
HIND's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HIND vs Medical Device Stocks
Vyome Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.